Analysis of Profitability Ratios
Quarterly Data
Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Profitability Ratios (Summary)
Intuitive Surgical Inc., profitability ratios (quarterly data)
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
- Gross Profit Margin
- The gross profit margin demonstrated a generally stable pattern, starting at 65.65% in Q1 2021 and showing a gradual increase to a peak of 69.32% in Q1 2022. Subsequently, the margin experienced a slight decline, stabilizing in the mid- to high-60 percent range through Q1 2025, ending at 67.09%. This suggests consistent cost management relative to revenue.
- Operating Profit Margin
- The operating profit margin exhibited an upward trend from 24.09% in Q1 2021 to a high of 32.55% in Q4 2021, indicating enhanced operational efficiency during this period. Following the peak, it declined steadily to 24.21% by Q1 2023, then gradually increased again to reach 28.20% by Q1 2025. This fluctuation indicates periods of varying operating cost control and profitability dynamics.
- Net Profit Margin
- Net profit margin trends paralleled the operating margin initially, rising from 24.33% in Q1 2021 to a peak of 31.43% in Q3 2021, followed by a decline through Q1 2023 down to 20.4%. Thereafter, a recovery phase led to a rise reaching 28.41% by Q1 2025. This indicates variability in the company’s ability to convert revenue into net income, potentially influenced by non-operating factors and expenses.
- Return on Equity (ROE)
- ROE showed a positive trajectory between Q1 2021 at 10.9% and Q3 2021 at 14.97%, after which it slightly decreased and stabilized around the 12% mark through early 2023. Starting mid-2023, ROE increased steadily, culminating at 14.47% by Q1 2025. This pattern reflects an improving capacity to generate profits from shareholders' equity over time with some interim fluctuations.
- Return on Assets (ROA)
- ROA increased from 9.5% in Q1 2021 to a peak of 13.2% in Q3 2021, followed by a decline and stabilization near 10-10.5% until early 2023. Subsequently, ROA climbed steadily to 12.88% by Q1 2025. These dynamics indicate varying efficiency in asset utilization for profit generation, with a strong rebound and improvement in the latter periods.
Return on Sales
Return on Investment
Gross Profit Margin
Intuitive Surgical Inc., gross profit margin calculation (quarterly data)
| Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
| Gross profit | 1,457,700) | 1,642,200) | 1,373,900) | 1,372,700) | 1,245,400) | 1,277,400) | 1,167,200) | 1,171,900) | 1,113,000) | 1,110,900) | 1,052,100) | 1,023,300) | 1,009,700) | 1,060,800) | 971,400) | 1,023,700) | 902,600) | 895,800) | 724,300) | 502,900) | 738,200) | |||||||
| Revenue | 2,253,400) | 2,413,500) | 2,038,100) | 2,009,900) | 1,890,600) | 1,928,300) | 1,743,700) | 1,755,900) | 1,696,200) | 1,655,000) | 1,557,400) | 1,522,100) | 1,487,700) | 1,550,700) | 1,403,300) | 1,464,000) | 1,292,100) | 1,329,100) | 1,077,700) | 852,100) | 1,099,500) | |||||||
| Profitability Ratio | ||||||||||||||||||||||||||||
| Gross profit margin1 | 67.09% | 67.46% | 66.98% | 66.86% | 66.43% | 66.39% | 66.61% | 66.74% | 66.86% | 67.44% | 67.77% | 68.16% | 68.84% | 69.32% | 69.12% | 68.69% | 66.48% | 65.65% | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||
| Gross Profit Margin, Competitors2 | ||||||||||||||||||||||||||||
| Abbott Laboratories | 51.50% | 50.93% | 50.96% | 50.53% | 50.27% | 50.28% | 49.97% | 50.23% | 50.66% | 51.54% | 52.60% | 53.54% | 52.44% | 52.21% | 52.01% | 50.69% | 51.25% | 50.49% | — | — | — | |||||||
| Elevance Health Inc. | 15.66% | 15.92% | 16.62% | 17.16% | 16.92% | 16.79% | 16.86% | 16.89% | 16.90% | 16.79% | 16.85% | 16.79% | 16.89% | 17.09% | 17.30% | 17.57% | 19.38% | 19.71% | — | — | — | |||||||
| Medtronic PLC | 65.16% | 65.34% | 65.50% | 65.40% | 65.68% | 65.67% | 66.43% | 67.21% | 67.61% | 67.98% | 67.89% | 67.39% | 66.53% | 65.19% | 63.85% | 64.57% | 65.76% | 67.41% | — | — | — | |||||||
| UnitedHealth Group Inc. | 20.98% | 21.31% | 21.91% | 22.63% | 23.18% | 23.64% | 24.16% | 24.08% | 24.20% | 24.09% | 23.74% | 23.51% | 23.31% | 23.60% | 23.75% | 23.80% | 25.79% | 25.62% | — | — | — | |||||||
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2025 Calculation
Gross profit margin = 100
× (Gross profitQ1 2025
+ Gross profitQ4 2024
+ Gross profitQ3 2024
+ Gross profitQ2 2024)
÷ (RevenueQ1 2025
+ RevenueQ4 2024
+ RevenueQ3 2024
+ RevenueQ2 2024)
= 100 × (1,457,700 + 1,642,200 + 1,373,900 + 1,372,700)
÷ (2,253,400 + 2,413,500 + 2,038,100 + 2,009,900)
= 67.09%
2 Click competitor name to see calculations.
- Revenue Trends
- Revenue shows a generally upward trajectory from March 2020 to March 2025. Starting at approximately $1.10 billion in March 2020, there is a cyclical pattern reflecting typical seasonal variations, with troughs around mid-year and peaks near year-end quarters. Notable growth periods include the increases from March 2021 to December 2021 and again from March 2023 to December 2024. The peak revenue recorded is around $2.41 billion in December 2024, before a slight decline to approximately $2.25 billion by March 2025.
- Gross Profit Trends
- Gross profit aligns closely with revenue trends, demonstrating an overall increase from about $738 million in March 2020 to over $1.45 billion by March 2025. The growth exhibits seasonal fluctuations similar to revenue, with quarter-end peaks more pronounced towards the latter years. Periodic dips in gross profit correspond to mid-year low revenue periods, but the general upward trend persists across the dataset, highlighting improved scale and business expansion.
- Gross Profit Margin
- Beginning in March 2021, gross profit margin is consistently reported and displays moderate stability. Values fluctuate within a narrow range between approximately 65.65% and 69.32%. After an initial increase through 2021, the margin stabilizes around 66% to 67% in subsequent years, indicating consistent cost management relative to sales despite revenue growth. There are slight improvements noted toward late 2024 peaking near 67.46%, which may suggest efficiency gains or favorable product mix during that period.
- Summary of Financial Performance
- The financial data indicates substantial growth in revenue and gross profit over the five-year span with maintained gross profit margins. The consistency in margin percentages alongside increasing absolute gross profit suggests effective cost control amidst rising sales volumes. Seasonal variations are evident, with recurring mid-year dampening effects on both revenue and gross profit, while year-end quarters typically exhibit higher values. The company's financial health, based on gross profitability metrics, shows improvement and sustained operational efficiency.
Operating Profit Margin
Intuitive Surgical Inc., operating profit margin calculation (quarterly data)
| Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
| Income from operations | 578,100) | 734,900) | 577,300) | 567,300) | 469,400) | 450,200) | 465,800) | 463,200) | 387,600) | 372,500) | 398,900) | 397,600) | 408,100) | 450,400) | 442,600) | 511,200) | 416,800) | 415,800) | 270,400) | 80,600) | 283,000) | |||||||
| Revenue | 2,253,400) | 2,413,500) | 2,038,100) | 2,009,900) | 1,890,600) | 1,928,300) | 1,743,700) | 1,755,900) | 1,696,200) | 1,655,000) | 1,557,400) | 1,522,100) | 1,487,700) | 1,550,700) | 1,403,300) | 1,464,000) | 1,292,100) | 1,329,100) | 1,077,700) | 852,100) | 1,099,500) | |||||||
| Profitability Ratio | ||||||||||||||||||||||||||||
| Operating profit margin1 | 28.20% | 28.12% | 26.24% | 25.79% | 25.26% | 24.80% | 24.66% | 24.34% | 24.21% | 25.35% | 27.05% | 28.48% | 30.69% | 31.89% | 32.55% | 31.27% | 26.01% | 24.09% | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||
| Operating Profit Margin, Competitors2 | ||||||||||||||||||||||||||||
| Abbott Laboratories | 16.84% | 16.27% | 16.24% | 15.92% | 15.76% | 16.15% | 15.02% | 15.23% | 16.77% | 19.16% | 20.95% | 22.42% | 20.73% | 19.56% | 20.04% | 18.46% | 17.97% | 15.48% | — | — | — | |||||||
| Elevance Health Inc. | 4.07% | 4.16% | 4.55% | 4.76% | 4.64% | 4.47% | 4.58% | 4.96% | 4.99% | 4.94% | 5.01% | 5.07% | 5.10% | 5.15% | 4.91% | 3.68% | 4.83% | 4.97% | — | — | — | |||||||
| Medtronic PLC | 15.82% | 15.89% | 17.50% | 17.41% | 17.83% | 17.56% | 18.17% | 19.02% | 19.37% | 18.15% | 17.89% | 16.68% | 14.78% | 14.89% | 11.44% | 12.77% | 14.25% | 16.57% | — | — | — | |||||||
| UnitedHealth Group Inc. | 8.27% | 8.17% | 8.28% | 8.40% | 8.58% | 8.80% | 8.86% | 8.83% | 8.87% | 8.83% | 8.65% | 8.32% | 8.19% | 8.40% | 7.91% | 7.73% | 9.24% | 8.76% | — | — | — | |||||||
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2025 Calculation
Operating profit margin = 100
× (Income from operationsQ1 2025
+ Income from operationsQ4 2024
+ Income from operationsQ3 2024
+ Income from operationsQ2 2024)
÷ (RevenueQ1 2025
+ RevenueQ4 2024
+ RevenueQ3 2024
+ RevenueQ2 2024)
= 100 × (578,100 + 734,900 + 577,300 + 567,300)
÷ (2,253,400 + 2,413,500 + 2,038,100 + 2,009,900)
= 28.20%
2 Click competitor name to see calculations.
The financial data reveals several notable trends over the analyzed quarters. Revenue demonstrates a general upward trajectory, moving from approximately $1.1 billion in the first quarter of 2020 to over $2.25 billion by the first quarter of 2025. There are fluctuations within certain quarters, but the overall growth is evident, reflecting a positive commercial performance and increasing market demand.
Income from operations exhibits more variability compared to revenue. It peaks notably at $734.9 million in the fourth quarter of 2024, indicating a strong operational efficiency during that period. However, income from operations also shows several declines and recoveries, with a low point around $80.6 million in the second quarter of 2020, which may reflect external challenges or internal operational adjustments. Despite these fluctuations, the general pattern remains upward, suggesting improvement in the company’s operational execution over time.
The operating profit margin, starting from the fourth quarter of 2020 as indicated, shows a consistent range between approximately 24% and 32%. It reached its highest point around 32.55% in the fourth quarter of 2021, followed by a slight downward correction but stabilizing around 25% to 28% in subsequent quarters. The stabilization of operating margins in the mid-to-high 20% range indicates a steady control over operating expenses relative to revenue, contributing to sustained profitability.
- Revenue Trends
- Steady increase from $1.1 billion in early 2020 to above $2.2 billion by early 2025, reflecting solid growth despite some quarterly variation.
- Income from Operations Trends
- Volatile initially with a low in Q2 2020, followed by significant growth culminating in a peak near $735 million in Q4 2024; indicative of increasing operational efficiency and resilience.
- Operating Profit Margin Analysis
- Operating margins consistently range from 24% to 32%, peaking at the end of 2021; margins remain robust and relatively stable, showing effective cost management and profitability sustainability.
Collectively, the data suggests progressive strengthening of operational performance alongside robust revenue expansion. While income from operations fluctuated in early periods, the path towards higher margins and increased earnings points to successful strategies in growth and expense management. The company appears to have effectively navigated challenges post-2020 to enhance its profitability position through 2025.
Net Profit Margin
Intuitive Surgical Inc., net profit margin calculation (quarterly data)
| Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
| Net income attributable to Intuitive Surgical, Inc. | 698,400) | 685,700) | 565,100) | 526,900) | 544,900) | 606,200) | 415,700) | 420,800) | 355,300) | 324,900) | 324,000) | 307,800) | 365,600) | 380,600) | 380,500) | 517,200) | 426,300) | 365,200) | 313,900) | 68,000) | 313,500) | |||||||
| Revenue | 2,253,400) | 2,413,500) | 2,038,100) | 2,009,900) | 1,890,600) | 1,928,300) | 1,743,700) | 1,755,900) | 1,696,200) | 1,655,000) | 1,557,400) | 1,522,100) | 1,487,700) | 1,550,700) | 1,403,300) | 1,464,000) | 1,292,100) | 1,329,100) | 1,077,700) | 852,100) | 1,099,500) | |||||||
| Profitability Ratio | ||||||||||||||||||||||||||||
| Net profit margin1 | 28.41% | 27.81% | 28.51% | 27.65% | 27.16% | 25.24% | 22.14% | 21.38% | 20.40% | 21.25% | 22.52% | 24.05% | 27.84% | 29.85% | 30.78% | 31.43% | 25.78% | 24.33% | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||
| Net Profit Margin, Competitors2 | ||||||||||||||||||||||||||||
| Abbott Laboratories | 31.89% | 31.95% | 13.99% | 13.65% | 13.96% | 14.27% | 12.92% | 12.83% | 13.98% | 15.88% | 17.52% | 18.78% | 17.35% | 16.42% | 17.12% | 15.85% | 15.33% | 12.99% | — | — | — | |||||||
| Elevance Health Inc. | 3.26% | 3.41% | 3.72% | 3.93% | 3.66% | 3.52% | 3.63% | 3.89% | 3.89% | 3.87% | 4.09% | 4.13% | 4.37% | 4.46% | 4.17% | 3.32% | 3.82% | 3.78% | — | — | — | |||||||
| Medtronic PLC | 12.05% | 11.36% | 13.00% | 12.84% | 11.47% | 12.03% | 13.20% | 14.03% | 16.75% | 15.90% | 15.46% | 14.79% | 12.29% | 11.97% | 10.36% | 12.69% | 15.80% | 16.56% | — | — | — | |||||||
| UnitedHealth Group Inc. | 5.46% | 3.65% | 3.68% | 3.70% | 4.09% | 6.09% | 6.09% | 6.11% | 6.21% | 6.25% | 6.21% | 5.99% | 5.91% | 6.06% | 5.56% | 5.37% | 6.46% | 6.03% | — | — | — | |||||||
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2025 Calculation
Net profit margin = 100
× (Net income attributable to Intuitive Surgical, Inc.Q1 2025
+ Net income attributable to Intuitive Surgical, Inc.Q4 2024
+ Net income attributable to Intuitive Surgical, Inc.Q3 2024
+ Net income attributable to Intuitive Surgical, Inc.Q2 2024)
÷ (RevenueQ1 2025
+ RevenueQ4 2024
+ RevenueQ3 2024
+ RevenueQ2 2024)
= 100 × (698,400 + 685,700 + 565,100 + 526,900)
÷ (2,253,400 + 2,413,500 + 2,038,100 + 2,009,900)
= 28.41%
2 Click competitor name to see calculations.
- Net Income
- The net income attributable to the company exhibits notable fluctuations over the observed periods. Starting at 313,500 thousand US dollars in March 2020, the value sharply declined to 68,000 thousand US dollars in June 2020, then rebounded markedly to 365,200 thousand US dollars by December 2020. Subsequently, net income remained relatively strong and displayed a general upward trend, reaching 698,400 thousand US dollars by March 2025. There are intermittent increases and decreases within this period, but the overall trajectory suggests significant growth in profitability over the long term.
- Revenue
- Revenue experienced variability in the early periods, decreasing from 1,099,500 thousand US dollars in March 2020 to 852,100 thousand US dollars in June 2020, before recovering to 1,329,100 thousand US dollars by December 2020. Subsequently, revenue showed a mostly consistent upward trend with occasional minor declines, culminating in a higher value of 2,253,400 thousand US dollars by March 2025. This indicates a sustained increase in sales and business activity despite short-term fluctuations.
- Net Profit Margin
- Net profit margin data is available starting from March 2021, showing a value of 24.33%. This margin increased to a peak of 31.43% in September 2021, followed by a gradual decline through the subsequent quarters, reaching around 20.4% in December 2022. After this trough, the profit margin improved steadily again, reaching approximately 28.41% by March 2025. This pattern indicates periods of higher profitability relative to revenue, with some volatility but an overall stable margin in the higher 20% range toward the end of the period.
- Summary
- The financial data reveals resilient company performance characterized by recovery from an initial downturn in early 2020. Both revenue and net income display positive growth over the analyzed periods, with revenue nearly doubling and net income more than doubling from early 2020 levels to early 2025. The net profit margin shows some variability but maintains an overall strong profile, reflecting improved operational efficiency or pricing power. The trends suggest a company successfully expanding its revenue base while managing profitability effectively despite fluctuating economic or market conditions.
Return on Equity (ROE)
Intuitive Surgical Inc., ROE calculation (quarterly data)
| Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
| Net income attributable to Intuitive Surgical, Inc. | 698,400) | 685,700) | 565,100) | 526,900) | 544,900) | 606,200) | 415,700) | 420,800) | 355,300) | 324,900) | 324,000) | 307,800) | 365,600) | 380,600) | 380,500) | 517,200) | 426,300) | 365,200) | 313,900) | 68,000) | 313,500) | |||||||
| Total Intuitive Surgical, Inc. stockholders’ equity | 17,106,400) | 16,433,700) | 15,583,300) | 14,708,300) | 13,962,600) | 13,307,600) | 12,539,000) | 11,879,100) | 11,217,700) | 11,041,900) | 11,515,400) | 12,023,000) | 12,102,300) | 11,901,100) | 11,410,900) | 10,837,500) | 10,153,500) | 9,731,500) | 9,257,800) | 8,740,500) | 8,506,700) | |||||||
| Profitability Ratio | ||||||||||||||||||||||||||||
| ROE1 | 14.47% | 14.13% | 14.39% | 14.23% | 14.24% | 13.51% | 12.10% | 12.00% | 11.70% | 11.98% | 11.97% | 11.93% | 13.58% | 14.32% | 14.80% | 14.97% | 11.56% | 10.90% | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||
| ROE, Competitors2 | ||||||||||||||||||||||||||||
| Abbott Laboratories | 27.66% | 28.12% | 14.49% | 14.13% | 14.51% | 14.83% | 13.77% | 13.88% | 15.68% | 18.90% | 22.11% | 23.44% | 21.82% | 19.75% | 21.04% | 18.86% | 17.06% | 13.71% | — | — | — | |||||||
| Elevance Health Inc. | 13.92% | 14.47% | 14.66% | 15.86% | 15.38% | 15.23% | 15.82% | 16.78% | 16.62% | 16.59% | 17.26% | 17.04% | 17.36% | 16.93% | 15.44% | 12.10% | 13.92% | 13.77% | — | — | — | |||||||
| Medtronic PLC | 8.19% | 7.32% | 8.11% | 7.97% | 7.07% | 7.30% | 7.90% | 8.33% | 9.88% | 9.59% | 9.35% | 9.05% | 7.54% | 7.01% | 5.70% | 7.05% | 8.77% | 9.44% | — | — | — | |||||||
| UnitedHealth Group Inc. | 23.26% | 15.55% | 15.14% | 15.78% | 17.72% | 25.22% | 25.67% | 25.63% | 25.46% | 25.87% | 26.03% | 25.07% | 23.98% | 24.09% | 21.95% | 21.03% | 25.42% | 23.52% | — | — | — | |||||||
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2025 Calculation
ROE = 100
× (Net income attributable to Intuitive Surgical, Inc.Q1 2025
+ Net income attributable to Intuitive Surgical, Inc.Q4 2024
+ Net income attributable to Intuitive Surgical, Inc.Q3 2024
+ Net income attributable to Intuitive Surgical, Inc.Q2 2024)
÷ Total Intuitive Surgical, Inc. stockholders’ equity
= 100 × (698,400 + 685,700 + 565,100 + 526,900)
÷ 17,106,400 = 14.47%
2 Click competitor name to see calculations.
The financial data demonstrates several notable trends over the observed periods. Net income attributable to the company exhibits a generally upward trajectory with some fluctuations. Starting from relatively lower levels around early 2020, there is a marked increase reaching a peak towards the end of 2023 and continuing strong into 2024 and early 2025. This growth indicates improved profitability and operational performance over time.
Total stockholders’ equity shows a consistent increase throughout the periods. This steady advancement suggests ongoing capital accumulation and potentially retained earnings contributing positively to the equity base. The equity growth aligns with the expanding net income, reflecting reinforcement of the company's financial foundation.
The Return on Equity (ROE) figures, available from the fourth quarter of 2020 onward, reveal a generally positive and fairly stable trend. Initial ROE values are around the low double digits, with a gradual increase toward mid-2021. The metric remains stable above 11% through 2022, and then shows an upward movement from late 2023 into 2024, approaching and surpassing 14%. This suggests improving efficiency in generating returns on shareholders’ equity, consistent with the rising net income.
Overall, the data presents a picture of sustained financial growth with strengthening profitability and equity generation capabilities. The steady increase in ROE further emphasizes effective management of equity resources to yield higher returns, supporting the company’s solid financial health trajectory during the analyzed timeframe.
Return on Assets (ROA)
Intuitive Surgical Inc., ROA calculation (quarterly data)
| Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
| Net income attributable to Intuitive Surgical, Inc. | 698,400) | 685,700) | 565,100) | 526,900) | 544,900) | 606,200) | 415,700) | 420,800) | 355,300) | 324,900) | 324,000) | 307,800) | 365,600) | 380,600) | 380,500) | 517,200) | 426,300) | 365,200) | 313,900) | 68,000) | 313,500) | |||||||
| Total assets | 19,220,400) | 18,743,200) | 17,743,400) | 16,649,900) | 15,828,000) | 15,441,500) | 14,712,700) | 13,903,300) | 13,053,200) | 12,974,000) | 13,260,800) | 13,705,200) | 13,678,400) | 13,555,000) | 12,934,600) | 12,297,000) | 11,540,400) | 11,168,900) | 10,617,500) | 10,103,600) | 9,891,100) | |||||||
| Profitability Ratio | ||||||||||||||||||||||||||||
| ROA1 | 12.88% | 12.39% | 12.64% | 12.57% | 12.56% | 11.64% | 10.31% | 10.25% | 10.05% | 10.19% | 10.39% | 10.47% | 12.02% | 12.58% | 13.06% | 13.20% | 10.17% | 9.50% | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||
| ROA, Competitors2 | ||||||||||||||||||||||||||||
| Abbott Laboratories | 16.58% | 16.46% | 7.76% | 7.61% | 7.77% | 7.82% | 7.16% | 7.04% | 7.87% | 9.31% | 10.84% | 11.53% | 10.44% | 9.40% | 9.82% | 8.70% | 7.86% | 6.20% | — | — | — | |||||||
| Elevance Health Inc. | 4.94% | 5.12% | 5.51% | 5.92% | 5.58% | 5.50% | 5.50% | 5.87% | 5.69% | 5.86% | 6.03% | 6.05% | 6.21% | 6.26% | 5.63% | 4.40% | 4.93% | 5.28% | — | — | — | |||||||
| Medtronic PLC | 4.38% | 4.09% | 4.63% | 4.55% | 3.99% | 4.13% | 4.32% | 4.63% | 5.79% | 5.54% | 5.35% | 5.13% | 4.23% | 3.87% | 2.97% | 3.69% | 4.70% | 5.28% | — | — | — | |||||||
| UnitedHealth Group Inc. | 7.14% | 4.83% | 4.78% | 4.93% | 5.40% | 8.18% | 7.69% | 7.53% | 7.30% | 8.19% | 7.99% | 7.93% | 7.89% | 8.15% | 7.24% | 6.90% | 8.23% | 7.81% | — | — | — | |||||||
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2025 Calculation
ROA = 100
× (Net income attributable to Intuitive Surgical, Inc.Q1 2025
+ Net income attributable to Intuitive Surgical, Inc.Q4 2024
+ Net income attributable to Intuitive Surgical, Inc.Q3 2024
+ Net income attributable to Intuitive Surgical, Inc.Q2 2024)
÷ Total assets
= 100 × (698,400 + 685,700 + 565,100 + 526,900)
÷ 19,220,400 = 12.88%
2 Click competitor name to see calculations.
The financial data reveals several notable trends over the observed periods. The net income attributable to the company exhibits significant fluctuations but overall displays an upward trajectory. Initial values start around 313,500 thousand US dollars in March 2020 with some volatility reported in mid-2020 and 2021, followed by a general increase reaching 698,400 thousand US dollars by March 2025. This indicates a strong growth pattern in profitability, particularly pronounced from late 2022 through early 2025.
Total assets demonstrate consistent growth over the timeframe. Starting from approximately 9,891,100 thousand US dollars in March 2020, the asset base expands steadily each quarter to reach over 19,220,400 thousand US dollars by March 2025. This steady accumulation of assets suggests ongoing investment and expansion efforts by the company, supporting its operational and growth strategies.
The Return on Assets (ROA) metric, though absent in the earliest periods, becomes available from December 2020 onwards and remains relatively stable with slight variations. ROA values range from approximately 9.5% to a peak of about 13.2% in early 2021, before stabilizing mostly between the range of 10% to nearly 13%. The ROA appears to improve incrementally from the end of 2022 through 2025, signaling enhanced efficiency in asset utilization to generate net income.
- Net Income Attributable to the Company
- Initial volatility observed in 2020 and early 2021 followed by a marked upward trend; highest figures recorded towards the end of the data set suggest strengthening profitability.
- Total Assets
- Shows a continuous and steady increase, indicating ongoing asset accumulation and potential capacity for growth and investment.
- Return on Assets (ROA)
- Stabilizes after initial measurement, with a general positive trend pointing to improved asset efficiency and profitability.